Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome

Neuroscience Letters

Volumn 482, Issue 3, 2010, Pages 216-219

  Shioda, Katsutoshi ^a   Nisijima, Koichi ^a   Yoshino, Tatsuki ^a   Kato, Satoshi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

5 HT1A receptor; 5 HT2A receptor; Hyperthermia; Mirtazapine; Serotonin syndrome

Indexed keywords

FLUOXETINE; MIRTAZAPINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; RITANSERIN; TRANYLCYPROMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HYPERTHERMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECTUM TEMPERATURE; SEROTONIN SYNDROME;

ANIMALS; BODY TEMPERATURE; DISEASE MODELS, ANIMAL; FEVER; MALE; MIANSERIN; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN ANTAGONISTS; SEROTONIN SYNDROME;

EID: 77955924234     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.07.039     Document Type: Article

References (30)

1. Benazzi F. Serotonin syndrome with mirtazapine-fluoxetine combination. Int. J. Geriat. Psychiatry 1998, 13:493-496.
2. Boddy R., Ali R., Dowsett R. Use of sublingual olanzapine in serotonin syndrome. J. Toxicol. Clin. Toxicol. 2004, 42:725.
3. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996, 14:87-96.
4. Dams R., Benijts T.H., Lambert W.E., Van Bocxlaer J.F., Van Varenbergh D., Van Peteghem C., De Leenheer A.P. A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication. J. Anal. Toxicol. 2001, 25:147-151.
5. De Boer T.H. The Pharmacologic profile of mirtazapine. J. Clin. Psychiatry 1996, 57:19-25.
6. De Boer T.H., Nefkens F., Van Helvoirt A., Van Delft A.M. Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J. Pharmacol. Exp. Ther. 1996, 277:852-860.
7. Demers J.C., Malone M. Serotonin syndrome induced by fluvoxamine and mirtazapine. Ann. Pharmacother. 2001, 35:1217-1220.
8. Gillman P.K. Mirtazapine: unable to induce serotonin toxicity?. Clin. Neuropharmacol. 2003, 26:288-289.
9. Gillman P.K. A review of serotonin toxicity: implications for the mechanisms of antidepressant drug action. Biol. Psychiatry 2006, 59:1046-1051.
10. Gudelsky G.A., Koenig J.I., Meltzer H.Y. Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors. Neuropharmacology 1986, 25:1307-1313.
11. Hernández J.L., Ramos F.J., Infante J., Rebollo M., González-Macías J. Severe serotonin syndrome induced by mirtazapine monotherapy. Ann. Pharmacother. 2002, 36:641-643.
12. Hilton S.E., Maradit H., Möller H.J. Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Eur. Arch. Psychiatry Clin. Neurosci. 1997, 247:113-119.
13. Hjorth S. Hypothermia in the rat induced by the potent serotoninergic agent 8-H-DPAT. J. Neural Transm. 1985, 61:131-135.
14. Hoes M.J., Zeijpveld J.H. Mirtazapine as treatment for serotonin syndrome. Pharmacopsychiatry 1996, 29:81.
15. Isbister G.K., Dawson A.H., Whyte I.M. Comment: serotonin syndrome induced by fluvoxamine and mirtazapine. Ann. Pharmacother. 2001, 35:1674-1675.
16. Isbister G.K., Whyte I.M. Adverse reactions to mirtazapine are unlikely to be serotonin toxicity. Clin. Neuropharmacol. 2003, 26:287-288.
17. Jacobs B.L. An animal behavior model for studying central serotonergic synapses. Life Sci. 1976, 19:777-786.
18. Klys M., Kowaiski P., Rojek S., Gross A. Death of a female cocaine user due to the serotonin syndrome following moclobemide-venlafaxine overdose. Forensic Sci. Int. 2009, 184:e16-20.
19. Manos G.H. Possible serotonin syndrome associated with buspirone added to fluoxetine. Ann. Pharmacother. 2000, 34:871-874.
20. Mazzola Pomietto P., Aulakh C.S., Wozniak K.M., Hill J.L., Murphy D.L. Evidence that 1-(2,5-dimethyoxy-4-iodophenyl)-2-amino-propane (DOI)-induced hyperthermia in rats is mediated by stimulation of 5-HT2A receptor. Psychopharmacology 1995, 117:193-199.
21. Mills K.C. Serotonin syndrome. Crit. Care Clin. 1997, 13:763-783.
22. 2A receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res. 2001, 890:23-31.
23. 1A receptor activation. Br. J. Pharmacol. 1992, 106:603-609.
24. 2A antagonist mirtazapine in rat model of thermoregulation. Brain Res. 2006, 1123:135-144.
25. Shioda K., Nisijima K., Yoshino T., Kato S. Extracellular serotonin, dopamine and glutamate levels are eleveated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine. Neuro-Psychopharmacol. Biol. Psychiatry 2004, 28:633-640.
26. K. Shioda, K. Nisijima, T. Yoshino, S. Kato, Effect of risperidone on methamphetamine-induced acute hyperthermia in rats, Drug Alcohol Depend., in press, doi:10.1016/j.neulet.2010.07.039.
27. Shioda K, Nisijima K., Yoshino T., Kuboshima K., Iwamura T., Yui K., Kato S. Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats. Neurotoxicology 2008, 29:1030-1036.
28. Spigset O., Adielsson G. Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interaction. Int. Clin. Psychopharmacol. 1997, 12:61-63.
29. Tricklebank M.D., Forler C., Fozard J.R. The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(DI-n-propylamino)tetralin in the rat. Eur. J. Pharmacol. 1985, 106:271-282.
30. Ubogu E.E., Katirji B. Mirtazapine-induced serotonin syndrome. Clin. Neuropharmacol. 2003, 26:54-57.